A Crossover Safety Study of Ferumoxytol Versus Placebo
This crossover safety study will evaluate the safety of a single dose of ferumoxytol compared to placebo in patients with chronic kidney disease.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Primary Purpose: Treatment
|Official Title:||A Double Blind, Placebo Controlled, Crossover Design, Multicenter Study of Intravenous Ferumoxytol Compared With Placebo|
- Safety evaluated by physical examinations, vital signs, laboratory tests and patient monitoring and evaluation.
|Study Start Date:||January 2005|
|Study Completion Date:||August 2006|
This is a double-blind, placebo controlled, crossover design study of the safety of ferumoxytol compared to placebo. Patients are randomized to receive either one 510 mg dose of ferumoxytol or the equivalent volume of normal saline followed by the other test article given one week later.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00255450
Show 41 Study Locations